BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu Y, Liu R, Dai Z. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing. Nanoscale 2020;12:21001-14. [PMID: 33078813 DOI: 10.1039/d0nr05452f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Putta S, Sharma RK, Khandelwal P. Metal Nanoparticles: Synthesis, Characterization, and Biomedical Applications. Nanomaterials 2023. [DOI: 10.1007/978-981-19-7963-7_4] [Reference Citation Analysis]
2 Chien Y, Hsiao Y, Chou S, Lin T, Yarmishyn AA, Lai W, Lee M, Lin Y, Lin T, Hwang D, Lin T, Chiou S, Chen S, Yang Y. Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities. J Nanobiotechnol 2022;20:511. [DOI: 10.1186/s12951-022-01717-x] [Reference Citation Analysis]
3 Chen C, Zhong W, Du S, Li Y, Zeng Y, Liu K, Yang J, Guan X, Han X. Intelligent nanotherapeutic strategies for the delivery of CRISPR system. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.12.013] [Reference Citation Analysis]
4 Rani V, Prabhu A. CRISPR-Cas9 based non-viral approaches in nanoparticle elicited therapeutic delivery. Journal of Drug Delivery Science and Technology 2022;76:103737. [DOI: 10.1016/j.jddst.2022.103737] [Reference Citation Analysis]
5 Qu S, Liu R, Zhang N, Xu Y, Yue X, Dai Z. Non-viral nucleic acid therapeutics: Revolutionizing the landscape of atherosclerotic treatment. Nano Today 2022;45:101514. [DOI: 10.1016/j.nantod.2022.101514] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Xi S, Yang Y, Suo J, Sun T. Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy. Front Bioeng Biotechnol 2022;10:873369. [DOI: 10.3389/fbioe.2022.873369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kaltenbacher T, Löprich J, Maresch R, Weber J, Müller S, Oellinger R, Groß N, Griger J, de Andrade Krätzig N, Avramopoulos P, Ramanujam D, Brummer S, Widholz SA, Bärthel S, Falcomatà C, Pfaus A, Alnatsha A, Mayerle J, Schmidt-Supprian M, Reichert M, Schneider G, Ehmer U, Braun CJ, Saur D, Engelhardt S, Rad R. CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver. Nat Protoc 2022. [PMID: 35288718 DOI: 10.1038/s41596-021-00677-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Jacob EM, Borah A, Sakthi Kumar D. CRISPR/Cas9 Nano-delivery Approaches for Targeted Gene Therapy. Nanotechnology in the Life Sciences 2022. [DOI: 10.1007/978-3-031-12658-1_2] [Reference Citation Analysis]
9 Kühn R. Genome engineering in rodents - status quo and perspectives. Lab Anim 2021;:236772211051842. [PMID: 34674587 DOI: 10.1177/00236772211051842] [Reference Citation Analysis]
10 Naeem M, Hoque MZ, Ovais M, Basheer C, Ahmad I. Stimulus-Responsive Smart Nanoparticles-Based CRISPR-Cas Delivery for Therapeutic Genome Editing. Int J Mol Sci 2021;22:11300. [PMID: 34681959 DOI: 10.3390/ijms222011300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Giordano F, Lenna S, Rampado R, Brozovich A, Hirase T, Tognon MG, Martini F, Agostini M, Yustein JT, Taraballi F. Nanodelivery Systems Face Challenges and Limitations in Bone Diseases Management. Adv Therap 2021;4:2100152. [DOI: 10.1002/adtp.202100152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv Drug Deliv Rev 2021;176:113891. [PMID: 34324887 DOI: 10.1016/j.addr.2021.113891] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
13 Ranjan A, Rajput VD, Minkina T, Bauer T, Chauhan A, Jindal T. Nanoparticles induced stress and toxicity in plants. Environmental Nanotechnology, Monitoring & Management 2021;15:100457. [DOI: 10.1016/j.enmm.2021.100457] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
14 Lee MH, Lin CC, Thomas JL, Li JA, Lin HY. Cellular reprogramming with multigene activation by the delivery of CRISPR/dCas9 ribonucleoproteins via magnetic peptide-imprinted chitosan nanoparticles. Mater Today Bio 2021;9:100091. [PMID: 33521619 DOI: 10.1016/j.mtbio.2020.100091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]